A Phase 1 interventional study of BIIB133 (Dapirolizumab pegol) and Placebo in Healthy Volunteers, sponsored by Biogen. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Biogen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to assess the safety and tolerability of a single intravenous (IV) dose of dapirolizumab pegol (DZP) in Japanese healthy study participants compared with those of Caucasian healthy study participants.
The secondary objectives of the study are to assess the pharmacokinetic(s) (PK) of a single IV dose of DZP in Japanese and Caucasian healthy study participants, to evaluate ethnic sensitivity on the PK of DZP between body weight- and gender-matched Japanese and Caucasian healthy study participants and to evaluate the immunogenicity of a single IV dose of DZP in Japanese and Caucasian healthy study participants.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single IV infusion of BIIB133 Dose 1.
Drug: BIIB133 (Dapirolizumab pegol)
Participants will receive single IV infusion of BIIB133 Dose 2.
Drug: BIIB133 (Dapirolizumab pegol)
Participants will receive single IV infusion of matching placebo to BIIB133.
Drug: Placebo
Administered as specified in the treatment arm
Also known as: DZP
Administered as specified in the treatment arm
Number of Participants with Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a birth defect.
Time frame: Up to Day 120
Plasma BIIB133 Concentration
Time frame: Up to Day 120
Area under Concentration-Time Curve from Time 0 to Infinity (AUCinf) of BIIB133
Time frame: Up to Day 120
Area under Concentration-Time Curve from Time 0 to Time t (AUC0-t) of BIIB133
Time frame: Up to Day 120
Maximum Observed Concentration (Cmax) of BIIB133
Time frame: Up to Day 120
Time to Reach Maximum Observed Concentration (Tmax) of BIIB133
Time frame: Up to Day 120
Elimination Half-life (t½) of BIIB133
Time frame: Up to Day 120
Clearance (CL) of BIIB133
Time frame: Up to Day 120
Volume of Distribution (Vd) of BIIB133
Time frame: Up to Day 120
Percentage of AUCinf Obtained by Extrapolation (AUCextr%) of BIIB133
Time frame: Up to Day 120
Area under Concentration-Time Curve from Time 0 to Infinity Normalized by Dose (AUCinf/Dose) of BIIB133
Time frame: Up to Day 120
Area under Concentration-Time Curve from Time 0 to Time t Normalized by Dose (AUC0-t/Dose) of BIIB133
Time frame: Up to Day 120
Maximum Observed Concentration Normalized by Dose (Cmax/Dose) of BIIB133
Time frame: Up to Day 120
Plasma Polyethylene Glycol (PEG) Concentration
Time frame: Up to Day 120
AUCinf of PEG
Time frame: Up to Day 120
AUC0-t of PEG
Time frame: Up to Day 120
Cmax of PEG
Time frame: Up to Day 120
Tmax of PEG
Time frame: Up to Day 120
t½ of PEG
Time frame: Up to Day 120
AUCextr% of PEG
Time frame: Up to Day 120
AUCinf/Dose of PEG
Time frame: Up to Day 120
AUC0-t/Dose of PEG
Time frame: Up to Day 120
Cmax/Dose of PEG
Time frame: Up to Day 120
Urine PEG Concentration
Time frame: Up to Day 120
Ratio of AUCinf of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of AUC0-t of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of Cmax of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of t½ of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of CL of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of Vd of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of AUCinf/Dose of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of AUC0-t/Dose of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Ratio of Cmax/Dose of BIIB133 between Japanese and Caucasian Participants
Time frame: Up to Day 120
Number of Participants with Anti-BIIB133 Antibodies
Time frame: Up to Day 120
Plasma Concentration of Anti-BIIB133 Antibodies
Time frame: Up to Day 120
Number of Participants with Anti-PEG Antibodies
Time frame: Up to Day 120
Plasma Concentration of Anti-PEG Antibodies
Time frame: Up to Day 120
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Ran from Oct 2020 to primary completion in Apr 2021, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapirolizumab pegol